3/11 Taiwan Life Sciences Biweekly Newsletter
2024-03-11 |
| Taiwan Life Sciences Biweekly |
| A Global Milestone in Innovative Pancreatic Cancer Therapy Press release 7 March, 2024 [Taiwan-based] BioGate Precision Medicine Corp., a member of Powerchip Group, held a press conference today to unveil an innovative breakthrough in pancreatic cancer drug development. Dr. Frank Huang, Chairman and CEO of BioGate, revealed that BioGate through in-house R&D has created a targeted therapy biologic, BGX. This was achieved by developing multi-platform technology combining biochemistry, immunology, and molecular biology. Studies of animals implanted with human pancreatic cancer cells confirm BGX's efficacy in inhibiting tumor growth and antiproliferation in metastasis, while extending survival rates. This achievement represents a major global milestone in pancreatic cancer treatment. BioGate also announced its plan to apply for TFDA Phase I clinical trials and to seek approval from the U.S. FDA, offering hope and improved care for pancreatic cancer patients in Taiwan region as well as worldwide. More... |
| Bora, Onyx Healthcare, and BioLASCO participate in Creative Life Science's NT$200 million cash increase 6 March, 2024 On the 4th, microbiological testing company Creative Life Science Co., Ltd. announced the recent completion of a NT$204 million cash increase, introducing strategic investors, including Bora Pharmaceuticals, Onyx Healthcare, and BioLASCO Taiwan, all listed biopharmaceutical companies. The company has also outlined plans for a public offering and listing on the Taiwan Stock Exchange in 2025. More... |
| Kaohsiung Chang Gung Discovery: Optimal model for brain stimulation therapy for bipolar disorder published in international journal 5 March, 2024 A team of researchers from Kaohsiung Chang Gung Memorial Hospital recently utilized evidence-based medicine methods of meta-analysis to identify four feasible non-invasive brain stimulation (NIBS) treatment modes for patients with bipolar disorder during depressive episodes. These modes include two types of transcranial magnetic stimulation (TMS) and two types of transcranial direct current stimulation (tDCS). The research findings have been published in the prestigious neuroscience journal Neuroscience and Biobehavioral Reviews. More... (in Chinese) |
| AI potential highlighted at biomedical forum 5 March, 2024 President Tsai Ing-wen and tech leaders at a conference on the biomedical industry yesterday praised the industry chain that has taken shape in Taiwan and artificial intelligence’s (AI) potential in healthcare. More... |
| Formosa Pharmaceuticals and AimMax Therapeutics Receive FDA Approval for Clobetasol Propionate Ophthalmic Suspension 0.05%, for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery Press release 4 March, 2024 Taiwan-based Formosa Pharmaceuticals (TW: 6838) and AimMax Therapeutics (United States) announced today that the U.S. Food and Drug Administration (FDA) has approved clobetasol propionate ophthalmic suspension 0.05% (APP13007), for the treatment of post-operative inflammation and pain following ocular surgery. More... |
| National Health Research Institutes and Kaohsiung Medical University reveal new target protein B-RAF, a dual precision strike against pancreatic cancer 4 March, 2024 Dr. Hung Wen-Chun, a distinguished researcher at the National Institute of Cancer Research of the National Health Research Institutes (NHRI), and the collaborative research team led by Professor Chen Li-Tzong of Kaohsiung Medical University, have for the first time confirmed that B-RAF (V-raf murine sarcoma viral oncogene homolog B1) is a novel RNF43 ubiquitination target protein. Furthermore, they have explained the key molecular mechanism by which RNF43 (ring finger protein 43) protein regulates B-RAF. This research was published in the renowned academic journal Advanced Science in January of this year. More... (in Chinese) |
| Quanta's Barry Lam to share trends in healthcare and technology 29 February, 2024 The IBMI 2024 Annual General Meeting will be held on 4 March. Barry Lam, founder of the Quanta Group and vice president of IBMI, will speak at the meeting and share his views on the latest trends in the healthcare and technology industries. More... |
| OBI Pharma subsidiary Obigen Pharma submits Phase II clinical trial application for OBI-858 to TFDA 29 February, 2024 OBI Pharma's (TW: 4174) subsidiary, Obigen Pharma, announced that it had submitted an application for Phase II clinical trials for OBI-858, a novel botulinum toxin developed by the company, to the Taiwan Food and Drug Administration (TFDA). More... (in Chinese) |
| Genetic mutation patterns among glioblastoma patients in the Taiwanese population - insights from a single institution retrospective study 28 February, 2024 This study utilized Next-Generation Sequencing (NGS) to explore genetic determinants of survival duration in Glioblastoma Multiforme (GBM) patients. … This study pioneers genetic analysis in Taiwanese GBM patients using NGS, advancing our understanding of their genetic landscape. More... |
| Steminent Biotherapeutics plans to submit IPO application in March 26 February, 2024 Steminent Biotherapeutics, a stem cell translational medicine drug development company (TW: 7729), in a recent interview stated that it plans to submit an application for an initial public offering (IPO) in March 2024. Additionally, it revealed that its drug Stemchymal, for Spinocerebellar Ataxia (SCA), will apply for drug approval in the Japanese market in 2024/2025. Steminent Biotherapeutics is currently establishing a PIC/S GMP factory for the production of Stemchymal. More... (in Chinese) |
| TTY Biopharm launches new antibiotics 25 February, 2024 To address the strong demand for drugs for infections, TTY Biopharm (TW: 4105) has been developing new antibiotics, including a Polymyxin B new drug with new efficacy and new applications for treating Gram-Negative bacteria. This antibiotic has now been approved by the Taiwan Food and Drug Administration (TFDA) and has obtained a drug license. TTY Biopharm will further strive to capture a slice of the approximately NT$5.4 billion market in the field of second-line antibiotic treatment. More... (in Chinese) |
| Taiwanese researchers create vitamin B1 rice 25 February, 2024 Taiwanese scientists have created a genetically modified rice strain that contains 25 to 30 percent more vitamin B1 without diminishing yield, research project head Hsieh Ming-hsiun said. More... |
| Alar Pharmaceuticals' anti-addiction drug to be included in research project by US-based Indivior 24 February, 2024 Alar Pharmaceuticals (TW: 6785) announced that its long-acting anti-addiction drug, ALA-1000, currently under development, has been designated as a key annual research and development project by the US-based pharmaceutical company Indivior PLC. This designation is expected to accelerate the recognition of subsequent research milestone payments, sales milestone payments, and global sales sharing after the product's market launch. More... (in Chinese) |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Contact: Daisy Tsai Tel: +886 2 27836028 ext 14 FAX : +886 2 27836027 Mobile: +886 933-139647 | Line ID : daisy222 Email: daisy@taiwanbio.org.tw BIO Asia-Taiwan 2024 (24-28 July, 2024) ========================================= Taiwan Bio Industry Organization (TBIO) Room C229, Bldg. C, No.99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |